Subsequently, the phase 1 NOA-16 and RESIST clinical trials were initiated to evaluate IDH-1R132H peptide vaccines in patients with newly diagnosed and recurrent glioma, respectively [234] (Supplementary Table S3). This evidence concerns the gene IDH1 and central nervous system cancer.